TABLE 2.

Effect of anti-MPER antibody adsorbtions on neutralization breadth

SubtypeVirusID50% Reductionc
BlankaMPERb
Adsorbed BB34 plasma
    HIV-2/HIV-1 MPERC1C4,8024199
    Subtype CCOT6.151,3506595
CAP85 97,1341,14084
CAP88 B5258<4084
CAP206 81,3508694
CAP210 B814810231
CAP228 512457370
CAP255 16164<4076
Du151.24846360
Du422.1155<4074
Du156.123,86915196
ZM197M.PB71,068<4096
ZM233M.PB62196670
ZM135M.PL10a1,65125085
    Subtype B6535.354910281
QHO692.421794277
CAAN5342.A21391297
TRO.11646<4094
SC422661.875817577
REJO4541.673318076
JR-FL129<4069
    Subtype A92RW0091,29682732
    Subtype D92UG0241,4801,00632
Adsorbed CAP206 plasma
    HIV-2/HIV-1 MPERC1C4,52722295
    Subtype CCOT6.151,23610991
CAP45 G34,72019396
CAP63 A918013227
CAP85 92,85635288
CAP88 B5223<4082
CAP206 81,8701,55517
Du151.2105<4062
Du422.11654772
Du156.126925792
Du172.17234<4083
ZM197M.PB73098273
ZM135M.PL10a2489163
    Subtype BQHO692.423836683
AC10.0.291114758
WITO4160.331449931
TRO.11491<4092
    Subtype A92RW00991579313
Q23.173203400
    Subtype D92UG0241,5561,26819
Adsorbed SAC21 plasma
    HIV-2/HIV-1 MPERC1C3,15724692
    Subtype CCOT6.15183<4078
CAP85 944727638
CAP88 B5884252
CAP206 836114061
CAP255 161091150
Du151.21176941
ZM197M.PB71178527
ZM233M.PB61007921
ZM135M.PL10a1,11430173
    Subtype BTRO.111474768
SC422661.888<4055
    Subtype A92RW0091,6651,04537
    Subtype D92UG0241,8891,49121
  • a ID50 of plasmas adsorbed on blank beads. These titers were similar to the ID50 obtained with the untreated sera.

  • b ID50 of plasmas adsorbed on beads coated with the MPER peptide.

  • c Percentage reduction in ID50 due to adsorption on MPER-coated beads (1 − MPER/blank). Cases where the percent reduction was >50% are in boldface.